QRxPharma Limited (QRX)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today Ľ it's FREE! Already a member? Login now!

General Information
Company Name: QRxPharma Limited
Stock Code: QRX
Website: www.qrxpharma.com
GICS Sub-Industry: Pharmaceuticals
Market Cap ($M): 3
Equiv. Shares (M): 164

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
$ 0.021 $ 0.021 $ 0.021 $ 0.020 $ 0.021 201,127 0%

Current Broker Consensus Recommendation more
Recommendation: Strong Buy (1)
Recommendation Date: 20th Aug 2014
Brokers Surveyed: 1

Company Overview

Business Description:
QRxPharma Limited (QRX) is a commercial-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and abuse prevention products. QRX conducts its operations in Australia.

Strategy Analysis:
In 2012, QRX plan to implement pre-launch messaging strategy, identify key geographic areas of concentration, implement MoxDue pre-launch promotional message and begin recruitment of additional Actavis territory managers. Beyond 2012, QRX strategy is to expand the sales force to 150-200. QRxPharma reported net loss of $5.21m, up 7.87% for the half-year ended 31 December 2012. Revenue from ordinary activities were $2.24m, down 26.89% from last year. Basic and Diluted EPS were (3.6) cents compared to (4) cents last year. The net operating cash outflow was $6.04m compared to an outflow of $1.92m in the pcp. No dividend was declared.

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014  A -13.3 -8.5 -- 0.0 0.0 0.0 --
2013  A -10.1 -7.0 -- 0.0 0.0 0.0 --
2012  A -15.9 -11.2 -- 0.0 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
Acrux Limited (ACR) $269 M 3.0384 -0.2238 1.9893 9.6131 12.3850 4.1432 12.38 5.86 6.40
Mayne Pharma Group (MYX) $441 M 1.0457 -0.0064 0.2830 23.9617 24.1158 18.7970 0.00 0.00 0.00
QRxPharma (QRX) $3 M -- -- -- -- -- -- 0.00 -- --

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
QRX -- -- 0.38 -- 5.53
Market 0.94 15.3 1.26 1.68 1.56
Sector 0.71 22.4 3.06 1.35 9.38

Name Position Start Date
Mr Bruce Alan Hancox Non-Executive Director 09 July 2014
Dr Richard Treagus Non-Executive Director 09 July 2014

Name Position
Edward Rudnic Chief Executive Officer
Edward M Rudnic Chief Operating Officer
Chris Campbell Company Secretary
M. Janette Dixon Vice President Global Business Development

Substantial Shareholders
Holding Name
18,822,019 (13.00%) Allan Gray Australia Pty Ltd
14,403,120 (9.95%) Auckland Trust Company Limited (ATF Second Pacific Master Superannuation Fund)
7,609,635 (5.26%) John Holaday

Calendar of Events
Date Event
25 September 2015 Report (Annual)
26 August 2015 Report (Prelim)
24 February 2015 Report (Interim)
29 October 2014 AGM
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Investing in Unlisted Property Trusts

A property trust allows you to buy 'units' in an investment operated by a professional investment manager. This Guide will help you understand the risks and decide whether to invest your money.

More details...


Billionaires bankroll Ten's new direction Media Network sees digital future

The Age 19/12/2013 | Ten Network's programming ambitions will be funded by a $200 million loan guaranteed by three of its billionaire owners, as the free-to-air broadcaster declared digital was the future and pointed to early signs that its switch to an older market demographic was working.

Elders alleges $24m fraud in live cattle division

The Age 19/12/2013 | Troubled rural services group Elders is threatening to call in the police over an alleged $24 million fraud by a "handful of individuals" in its live cattle exports division.

Bega Cheese holds back in three-way bidding war for WCB

The Age 19/12/2013 | Bega Cheese began the battle for Warrnambool Cheese & Butter but three months on it appears to be the first casualty of the bidding war.

Aussie hampers transition

The Age 19/12/2013 | A persistently high Australian dollar is thwarting the Reserve Bank's efforts to ease the transition of the economy away from mining.

RBA keeps its focus on lower dollar

The Age 19/12/2013 | The Reserve Bank is keeping the door open to further interest rate cuts, but believes the "significant amount" of monetary policy easing over the past two years is already stimulating growth.

Pact's struggles weigh down Orora

The Age 19/12/2013 | The underwhelming sharemarket debut of packaging company Pact Group Holdings has weighed on the demerger of Amcor and its $2 billion Australasian packaging and distribution business Orora.


Sponsored Links